These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36826420)

  • 41. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
    Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
    JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
    Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
    Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
    Tanabe N; Saeki I; Aibe Y; Matsuda T; Hanazono T; Nishi M; Hidaka I; Kuwashiro S; Shiratsuki S; Matsuura K; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Sasaki R; Nishimura T; Oono T; Hisanaga T; Matsumoto T; Ishikawa T; Yamasaki T; Takami T
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A Case of Successful Treatment of Recurrent Peritoneal Dissemination of Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Combination Therapy].
    Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Shinke G; Katsuyama S; Ikeshima R; Kawai K; Hiraki M; Sugimura K; Masuzawa T; Takeno A; Hata T; Murata K
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):2027-2029. PubMed ID: 35045482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
    Kim C; Yang H; Kim I; Kang B; Kim H; Kim H; Lee WS; Jung S; Lim HY; Cheon J; Chon HJ
    JAMA Oncol; 2022 Dec; 8(12):1825-1829. PubMed ID: 36264560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report.
    Uchida K; Ozono Y; Uchiyama N; Hatada H; Nakamura K; Komaki Y; Iwakiri H; Hasuike S; Nagata K; Sato Y; Kawakami H
    Medicine (Baltimore); 2022 Sep; 101(35):e30486. PubMed ID: 36107543
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Niizeki T; Tokunaga T; Takami Y; Wada Y; Harada M; Shibata M; Nakao K; Sasaki R; Hirai F; Shakado S; Yoshizumi T; Itoh S; Yatsuhashi H; Bekki S; Ido A; Mawatari S; Honda K; Sugimoto R; Senju T; Takahashi H; Kuwashiro T; Maeshiro T; Nakamuta M; Aratake Y; Yamashita T; Otsuka Y; Matsumoto S; Sohda T; Shimose S; Murotani K; Tanaka Y
    Target Oncol; 2022 Nov; 17(6):643-653. PubMed ID: 36272060
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy.
    Chouik Y; Erard D; Demian H; Schulz T; Mazard T; Hartig-Lavie K; Antonini T; Mabrut JY; Mohkam K; Rode A; Merle P
    Front Immunol; 2023; 14():1205997. PubMed ID: 37377975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report.
    Cho SH; You GR; Park C; Cho SG; Lee JE; Choi SK; Cho SB; Yoon JH
    World J Gastrointest Oncol; 2023 May; 15(5):892-901. PubMed ID: 37275450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
    Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Kawano Y; Morishita A; Okamoto K; Sogabe M; Miyamoto H; Masaki T; Takayama T
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
    Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
    BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab.
    Hsu C; Ducreux M; Zhu AX; Qin S; Ikeda M; Kim TY; Galle PR; Finn RS; Chen E; Ma N; Hu Y; Li L; Cheng AL
    Liver Cancer; 2023 Feb; 12(1):44-56. PubMed ID: 36872921
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial.
    Lee YC; Huang WT; Lee MY; Tsao CJ; Feng YH
    In Vivo; 2023; 37(1):454-460. PubMed ID: 36593061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Shimose S; Iwamoto H; Shirono T; Tanaka M; Niizeki T; Kajiwara M; Itano S; Yano Y; Matsugaki S; Moriyama E; Noda Y; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
    Cancer Med; 2023 Jun; 12(11):12325-12335. PubMed ID: 37062077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
    Xin Y; Cao F; Yang H; Zhang X; Chen Y; Cao X; Zhou X; Li X; Zhou J
    Front Immunol; 2022; 13():929141. PubMed ID: 35990634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rare infiltrative primary hepatic angiosarcoma: A case report and review of literature.
    Lin XJ; Luo HC
    World J Gastrointest Oncol; 2024 Jul; 16(7):3341-3349. PubMed ID: 39072148
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis.
    Hatanaka T; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kumada T; ;
    Hepatol Res; 2022 May; 52(5):462-470. PubMed ID: 35080087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
    Takaki S; Kurosaki M; Mori N; Tsuji K; Ochi H; Marusawa H; Nakamura S; Tada T; Narita R; Uchida Y; Akahane T; Kondo M; Kusakabe A; Furuta K; Kobashi H; Arai H; Nonogi M; Tamada T; Hasebe C; Ogawa C; Sato T; Tamaki N; Yasui Y; Tsuchiya K; Izumi N
    Invest New Drugs; 2023 Apr; 41(2):340-349. PubMed ID: 36995548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serial Changes of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
    Murata Y; Nosaka T; Akazawa Y; Tanaka T; Takahashi K; Naito T; Matsuda H; Ohtani M; Nakamoto Y
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.